Expectats for October, page-2

I guess if JF & Co. fail to cross off any of these in October, you can always start another thread titled "Expectations in November" as they are bound to want to release information in the lead up to the AGM for obvious reasons ?


After making these statements on DEP® Cabazitaxel almost 6 months ago (below) and reiterating them in every corresponding ASX announcement since, you would think they would have delivered something in the Sept quarter from these open label trials .... nope



At this stage, Starpharma expects to report top-line results from the Phase 2 clinical trial of DEP® cabazitaxel during Q3 CY23, following the final requisite data verification and review. In parallel, licensing activities and discussions for DEP® cabazitaxel are ongoing as part of the Company’s DEP® commercialisation strategy.